

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



13 April 2021

UBI signs exclusive deal with Deakin and Swinburne for the development of biosensors, including cancer biosensor (Tn Antigen)

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce that it has entered into exclusive agreements with Deakin University's Institute for Frontier Materials (**DIFM**) and Swinburne University of Technology (**Swinburne**) to:

- commercialize the Tn Antigen (**Tn**) biosensor used for the detection, staging and monitoring of cancer; and
- Develop other biosensors using UBI electrochemical platform technology.

The DIFM agreement contracts 50% of DIFM Senior Fellow Dr. Wren Green's time and resources to UBI. The agreement is for a 5-year term, is for a fixed fee and can be terminated with 30 days notice.

The Swinburne agreement contracts 80% of Dr Saimon Moraes Silva's time under the supervision of Professor Simon Moulton of Swinburne's School Software and Electrical Engineering and Iverson Health Innovation Research Institute to UBI. The agreement is for a fixed fee and ends in February 2022 but can be extended by mutual agreement.

Both agreements have fee's payable by UBI which collectively should not exceed \$300,000 pa.

John Sharman, CEO of UBI said; "DIFM and Swinburne have been working on the next generation of electrochemical biosensors and the Tn Antigen cancer biomarker for more than 5 years. Using UBI's platform technology we plan to deliver a cancer biosensor capable of identifying, staging and monitoring cancer from a finger prick of blood, using a portable hand held device. The knowledge and resources of DIFM and Swinburne will help deliver this as well as fast track the development of other biosensors we are working on"

End

Enquiries:
John Sharman
Chief Executive Officer
+61 (0) 414 440 680

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

About Universal Biosensors

For additional information regarding Universal Biosensors, Inc., refer to:

<http://www.universalbiosensors.com>. Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), food and drink and agriculture.

About Deakin Institute for Frontier Materials

The Institute for Frontier Materials (IFM) at Deakin University is a leading materials science research institute. Researchers come from all over the world and from many different research areas, including engineering, chemistry, textile science and molecular modelling. IFM metallurgy and materials researchers, working with researchers in artificial intelligence have created cutting-edge software that accelerates alloy design and optimises alloy processes, compared to traditional “trial and error” techniques. The IFM Vision is to lead and inspire innovations in materials science and engineering that have a transformational benefit to society. The IFM Mission is to create and translate knowledge at the frontier of materials science for globally raised standards of living by: Re-designing materials for a circular economy; Imparting materials with extraordinary functionality. For more information visit <https://ifm.deakin.edu.au/about-us/>

About Swinburne University

Swinburne’s Department of Telecommunications, Electrical, Robotics and Biomedical Engineering provides courses in all areas of telecommunications, robotics, biomedical engineering and electrical engineering. Our research strengths include artificial intelligence in manufacturing, automation and control systems, electric vehicles, power system stability and control and signal and image processing. The biomedical engineering faculty applies electronics and systems engineering in health and biology, along with medical instrumentation and prosthetic devices.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.